Acer Therapeutics Inc. (NASDAQ: ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately held Acer Therapeutics Inc. See September 19, 2017 press release found here for more details.
Focus On Rare And Ultra Rare Diseases
The Company's business plan is to acquire commercial or near commercial stage orphan or ultra orphan drugs to treat rare and ultra rare diseases with critical unmet medical needs. The initial